Algenex
Contact information
- Vaccines
- Animal health / Veterinary
Algenex is a privately held biotechnology company that develops disruptive baculovirus-based technologies for the production of recombinant biological products.
Algenex has successfully developed more than 200 molecules—including VLP-based vaccines, monomeric vaccines, diagnostic reagents, enzymes, and growth factors—in collaboration with public and private partners, including several international pharmaceutical companies. More recently, the company has entered the human health field, with the aim of leveraging the advantages of CrisBio® for the production of vaccines and other much-needed pharmaceutical products.
Algenex’s first two platforms, TopBac® and CrisBio®, are based on baculovirus expression systems and have demonstrated their ability to transform recombinant protein production through a process that provides virtually unlimited and immediate manufacturing scalability, production flexibility, simplicity, and highly cost-effective versatility.
Business lines:
- Licensing of the rights to use its technology platforms for recombinant protein production, both during the development phase and for commercial purposes;
- Supply of reagents for diagnostic kits or co-development of such kits;
- Vaccine development in collaboration with external partners;
- Licensing for the use of its immunopotentiating molecule in veterinary and human vaccines.
Financing, Internationalization and Technological Transformation